Edasalonexent in Development for the Treatment of Duchenne: Information on Three Clinical Trials

Join to learn about edasalonexent, a novel oral NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy, regardless of mutation type.

This webinar will include:

• An update on the currently enrolling global Phase 3 PolarisDMD trial
• An introduction to the open-label extension GalaxyDMD trial
• Results from the Phase 2 MoveDMD trial